

Juan E Grunwald

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5254814/juan-e-grunwald-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62
papers

6,969
citations

32
h-index

64
g-index

64
ext. papers

8,200
ext. citations

6.3
avg, IF

5.48
L-index

#	Paper	IF	Citations
62	BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , 2021 , 41, 125-134	3.6	1
61	Progression of retinopathy and incidence of cardiovascular disease: findings from the Chronic Renal Insufficiency Cohort Study. <i>British Journal of Ophthalmology</i> , 2021 , 105, 246-252	5.5	3
60	Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>American Journal of Ophthalmology</i> , 2021 , 223, 338-347	4.9	1
59	SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , 2021 , 41, 1455-1462	3.6	1
58	Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology Retina</i> , 2021 , 5, 962-974	3.8	3
57	Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. <i>Ophthalmology</i> , 2020 , 127, S135-S145	7.3	18
56	Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2020 , 138, 276-284	3.9	2
55	Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. <i>JAMA Ophthalmology</i> , 2020 , 138, 510-518	3.9	6
54	Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial. <i>Ophthalmology Retina</i> , 2020 , 4, 889-898	3.8	8
53	Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4. <i>Ophthalmology</i> , 2020 , 127, 394-409	7.3	67
52	Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT). <i>JAMA Ophthalmology</i> , 2019 , 137, 1306-1311	3.9	3
51	Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2019 , 126, 743-751	7.3	14
50	Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>JAMA Ophthalmology</i> , 2019 , 137, 767-774	3.9	11
49	Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT. <i>Ophthalmology Retina</i> , 2019 , 3, 316-325	3.8	10
48	ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. <i>Retina</i> , 2019 , 39, 1965-1972	3.6	2
47	Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2019 , 126, 252-260	7.3	83
46	Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2018 , 125, 1037-1046	7.3	37

45	Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study. <i>Atherosclerosis</i> , 2018 , 271, 53-60	3.1	37
44	Linking OCT, Angiographic, and Photographic Lesion Components in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2018 , 2, 481-493	3.8	2
43	Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials. <i>JAMA Ophthalmology</i> , 2018 , 136, 682-688	3.9	12
42	Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort). <i>Hypertension</i> , 2018 , 71, 1101-1107	8.5	62
41	Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials. <i>Ophthalmology Retina</i> , 2018 , 2, 525-530	3.8	28
40	Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. <i>Ophthalmology</i> , 2018 , 125, 537-548	7.3	253
39	Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. <i>Ophthalmology</i> , 2017 , 124, 464-478	7.3	110
38	Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology Retina</i> , 2017 , 1, 25-33	3.8	5
37	Association between pseudodrusen and delayed patchy choroidal filling in the comparison of age-related macular degeneration treatments trials. <i>Acta Ophthalmologica</i> , 2017 , 95, e518-e520	3.7	4
36	Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2017 , 124, 97-104	7.3	113
35	Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>Ophthalmology</i> , 2016 , 123, 609-16	7.3	66
34	Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016 , 123, 352-360	7.3	25
33	Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016 , 123, 858-64	7.3	10
32	Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016 , 123, 865-75	7.3	129
31	Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016 , 123, 1530-40	7.3	63
30	Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>JAMA Ophthalmology</i> , 2016 , 134, 674-81	3.9	12
29	Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016 , 123, 1751-1761	7.3	389
28	Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2015 , 122, 1846-53.e5	7.3	96

27	Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2015 , 122, 1203-11	7.3	43
26	Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. <i>Ophthalmology</i> , 2015 , 122, 809-16	7.3	159
25	Retinopathy and the risk of cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort study). <i>American Journal of Cardiology</i> , 2015 , 116, 1527-33	3	11
24	Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). <i>Ophthalmology</i> , 2015 , 122, 2523-31.e1	7.3	67
23	Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). <i>Ophthalmology</i> , 2015 , 122, 391-398.e5	7.3	40
22	Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>American Journal of Ophthalmology</i> , 2014 , 158, 525-31.e2	4.9	7
21	Risk of scar in the comparison of age-related macular degeneration treatments trials. <i>Ophthalmology</i> , 2014 , 121, 656-66	7.3	175
20	Author reply: To PMID 24084496. <i>Ophthalmology</i> , 2014 , 121, e35	7.3	6
19	Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. <i>Ophthalmology</i> , 2014 , 121, 150-161	7.3	375
18	Retinopathy and progression of CKD: The CRIC study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 1217-24	6.9	21
17	Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. <i>JAMA Ophthalmology</i> , 2014 , 132, 915-21	3.9	65
16	Retinopathy and CKD as predictors of all-cause and cardiovascular mortality: National Health and Nutrition Examination Survey (NHANES) 1988-1994. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 198-203	7.3	26
15	Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. <i>Ophthalmology</i> , 2013 , 120, 2035-41	7.3	68
14	Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. <i>Ophthalmology</i> , 2013 , 120, 122-9	7.3	221
13	Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. <i>Ophthalmology</i> , 2013 , 120, 1860-70	7.3	173
12	Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2012 , 119, 1634-41	7.3	50
11	Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. <i>Ophthalmology</i> , 2012 , 119, 1388-98	7.3	1317
10	Association between retinopathy and cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC] Study). <i>American Journal of Cardiology</i> , 2012 , 110, 246-53	3	38

9	Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) study. <i>JAMA Ophthalmology</i> , 2012 , 130, 1136-44		92
8	Ranibizumab and bevacizumab for neovascular age-related macular degeneration. <i>New England Journal of Medicine</i> , 2011 , 364, 1897-908	59.2	1923
7	Prevalence of ocular fundus pathology in patients with chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 867-73	6.9	48
6	Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. <i>Investigative Ophthalmology and Visual Science</i> , 2005 , 46, 1033-8		240
5	Effect of sildenafil citrate (Viagra) on retinal blood vessel diameter. <i>American Journal of Ophthalmology</i> , 2002 , 133, 809-12	4.9	54
4	Effect of oral felodipine on ocular circulation. <i>International Ophthalmology</i> , 1999 , 23, 79-84	2.2	11
3	Effects of dorzolamide hydrochloride 2% on the retinal circulation. <i>Acta Ophthalmologica</i> , 1997 , 75, 236-8		40
2	Short-term effects of topical levobunolol on the human retinal circulation. <i>Eye</i> , 1997 , 11 (Pt 3), 371-6	4.4	7
1	Effect of one week of levobunolol HCl 0.5% on the human retinal circulation. <i>Current Eye Research</i> , 1997 , 16, 191-6	2.9	5